Ipilimumab and nivolumab for recurrent neuroendocrine cervical carcinoma

Mary Towner, Karen Novak, Young Kwang Chae, Daniela Matei*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Neuroendocrine carcinoma of the cervix is a rare subtype of cervical cancer with a poor prognosis. Primary treatment of this disease involves a combination of surgery, chemotherapy, and radiation. The majority of patients will experience disease recurrence, for which there exist no treatment guidelines. Because of histologic similarities, small cell lung cancer has often informed management of extrapulmonary neuroendocrine carcinomas. Immunotherapy regimens, including a combination of ipilimumab and nivolumab, have been shown to have activity in small cell lung cancer. In this report, we present the cases of 3 patients with recurrent neuroendocrine carcinoma of the cervix who experienced durable response to a combination of ipilimumab and nivolumab.

Original languageEnglish (US)
Article number101039
JournalGynecologic Oncology Reports
Volume42
DOIs
StatePublished - Aug 2022

Keywords

  • Immunotherapy
  • Ipilimumab
  • Neuroendocrine carcinoma of the cervix
  • Nivolumab

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Fingerprint

Dive into the research topics of 'Ipilimumab and nivolumab for recurrent neuroendocrine cervical carcinoma'. Together they form a unique fingerprint.

Cite this